Fraterno Marc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fraterno Marc has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Altié
Aix Marseille Université, INSERM 1263, INRAE, C2VN, 13885 Marseille, France
2 shared publications - Benoit Bordignon
Montpellier Ressources Imagerie BioCampus, Univ Montpellier, CNRS, INSERM , Montpellier 34298
2 shared publications - Burkhard Gess
Department of Neurology, RWTH University Hospital Aachen, Aachen, Germany
2 shared publications - Franck Peiretti
Aix Marseille Univ, INSERM, INRA, NORT, Marseille, France
2 shared publications - Frédéric Bihel
Laboratoire d’Innovation Thérapeutique, UMR 7200 CNRS, Université de Strasbourg
2 shared publications - Michel Fontes
Centre de recherche en CardioVasculaire et Nutrition, Aix-Marseille Université, INRA 1260—INSERM 1263, 13005 Marseille, France
2 shared publications
Latest Publications
- Open Access
- 25 January 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 6
Erratum to: CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors
- 25 January 2016
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 11 (1) , 6
Open AccessErratum to: CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors
- Open Access
- 7 May 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-6
CMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.
- 7 May 2015
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 10 (1) , 1-6
Open AccessCMTX1 patients’ cells present genomic instability corrected by CamKII inhibitors
We previously described that fibroblasts from animal models of CMTX1 present genomic instability and poor connexon activity. In vivo, these transgenic mice present motor deficits. This phenotype could be significantly reverted by treatment with (CamKII) inhibitors. The objective of this study is to translate our findings to patients. We cultured fibroblasts from skin biopsies of CMTX1 patients and analyzed cells for genomic instabilty, connexon activity, and potential correction by CamKII inhibitors. The phenotypic analysis of these cells confirmed strong similarities between the GJB1 transgenic mouse cell lines and CMTX1 patient fibroblast cell lines. Both present mitotic anomalies, centrosome overduplication, and connexon activity deficit. This phenotype is corrected by CamKII inhibitors. Our data demonstrate that fibroblasts from CMTX1 patients present a phenotype similar to transgenic lines that can be corrected by CamKII inhibitors. This presents a track to develop therapeutic strategies for CMTX1 treatment.